A class action lawsuit has been filed against Phreesia, Inc. alleging securities fraud. The complaint claims the company made false statements about its business prospects while experiencing slowing demand, diminished revenue visibility, and weakened pharmaceutical marketing commitments in its Network Solutions segment during the period from May 8, 2025 to March 30, 2026.

The DJS Law Group has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) for securities law violations under the Securities Exchange Act of 1934. The lawsuit alleges that Phreesia made false and misleading statements regarding its pharmaceutical marketing commitments as a growth engine for its Network Solutions segment while knowing of industry uncertainty that would impact revenue guidance. The class period spans May 8, 2025 to March 30, 2026, with a deadline of July 13, 2026 for shareholders to join the case.

Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Phreesia Inc. for alleged securities fraud. The company allegedly misrepresented its revenue growth outlook and minimized risks in its Network Solutions segment. On March 30, 2026, Phreesia announced significantly lowered fiscal 2027 revenue projections, causing its stock to plummet 26.6% to $8.38 per share. Investors who purchased shares between May 8, 2025 and March 30, 2026 can file a lead plaintiff motion by July 13, 2026.

Rosen Law Firm has filed securities class action lawsuits against Phreesia Inc., Zoetis Inc., and ChampionX Corporation on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made false or misleading statements regarding business conditions, including slowing demand and reduced visibility in key revenue streams.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Veritone, Inc. (VERI), where the company allegedly made false statements about revenue and financial performance, maintained deficient internal controls, and will need to restate financial statements. The lead plaintiff deadline is July 20, 2026. Similar notices were issued for Phreesia, Inc. (PHR) and Stellantis N.V. (STLA).

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Phreesia, Inc. (PHR), where investors who purchased stock between May 8, 2025 and March 30, 2026 may be entitled to compensation. The lawsuit alleges Phreesia made false statements about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. Additional class actions are mentioned for Veritone, Inc. (VERI) and Stellantis N.V. (STLA). The lead plaintiff deadline for the Phreesia case is July 13, 2026.

Phreesia Inc. faces a securities fraud class action lawsuit after the company announced significantly lowered revenue growth projections for fiscal 2027 on March 30, 2026, citing macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% following the announcement. Shareholders who purchased stock between May 8, 2025 and March 30, 2026 have until July 13, 2026 to file a lead plaintiff motion.

A securities fraud class action lawsuit has been filed against Phreesia Inc. after the company announced significantly lowered revenue growth projections for fiscal 2027 on March 30, 2026, citing macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% following the announcement. Investors who purchased shares between May 8, 2025 and March 30, 2026 have until July 13, 2026 to file a lead plaintiff motion.

The Schall Law Firm is seeking investors who purchased Phreesia, Inc. securities between May 8, 2025 and March 30, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its long-term growth outlook and fiscal year 2027 projections, particularly regarding pharmaceutical marketing commitments as a growth driver for its Network Solutions segment. Investors who suffered losses are encouraged to contact the firm before July 13, 2026.

Robbins LLP has filed a class action lawsuit against Phreesia, Inc. on behalf of investors who purchased stock between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia misled investors regarding the sustainability of growth in its Network Solutions business and fiscal 2027 revenue outlook. The company failed to disclose weakening pharmaceutical marketing commitments and reduced visibility into future spending. On March 30, 2026, Phreesia lowered its fiscal 2027 revenue guidance from $545-$559 million to $510-$520 million, causing the stock to plunge approximately 27% in a single day.

A securities fraud class action lawsuit has been filed against Phreesia Inc. after the company announced significantly lowered revenue growth projections for fiscal 2027 on March 30, 2026, citing macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% to $8.38 per share following the announcement. Investors who purchased shares between May 8, 2025 and March 30, 2026 may seek lead plaintiff status by July 13, 2026.

A federal securities class action lawsuit has been filed against Phreesia, Inc. for allegedly making materially false and misleading statements regarding slowing demand and reduced visibility in its Network Solutions segment, particularly regarding weakened pharmaceutical marketing commitments. The company had provided optimistic fiscal 2027 revenue guidance in December 2025 but significantly reduced projections on March 30, 2026, causing a 27% stock price decline. The deadline to seek lead plaintiff status is July 13, 2026.